Loading…
First Tracks Biotherapeutics, Inc. is projected to decline to $15.84 by 2027, a -2% move from its current price of $16.14. Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $15.32 | $16.14 | $17.01 | +0.02% |
| May 30 | $15.00 | $16.15 | $17.38 | +0.05% |
| May 31 | $14.76 | $16.15 | $17.68 | +0.07% |
| Jun 1 | $14.55 | $16.16 | $17.93 | +0.10% |
| Jun 2 | $14.38 | $16.16 | $18.16 | +0.12% |
| Jun 3 | $14.22 | $16.16 | $18.37 | +0.14% |
| Jun 4 | $14.08 | $16.17 | $18.56 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.08 | $16.17 | $18.56 | +0.17% |
| Week 2 | $13.32 | $16.19 | $19.69 | +0.34% |
| Week 3 | $12.77 | $16.22 | $20.61 | +0.51% |
| Week 4 | $12.33 | $16.25 | $21.42 | +0.68% |
| Week 5 | $11.95 | $16.28 | $22.16 | +0.85% |
| Week 6 | $11.63 | $16.30 | $22.87 | +1.02% |
| Week 7 | $11.33 | $16.33 | $23.53 | +1.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. Its work centers on developing therapies that modulate immune pathways to treat inflammatory conditions and autoimmune diseases.
The company’s product lineup includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, an antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).
First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. The company was founded in 2019 and is based in San Diego, California. The entity operates within the Healthcare category.
The company was founded in 2019 and is based in San Diego, California. The description reflects its focus on clinical-stage biotechnology and immunology therapeutics in the United States, with a trio of listed product candidates.
TRAX is the ticker for First Tracks Biotherapeutics, Inc., which currently trades at $17.18 per share and has a market capitalization of $599.45M. The stock is ranked 2901 among listed equities. The forecast suggests an overall price trajectory with bullish sentiment emerging from 2028 onward, culminating in higher average prices by 2050.
The forecast indicates an overall upside, with the 2050 average price projected at $58.68 and the 2050 maximum forecast at $134.96, alongside positive ROI figures in later years. The current price of $17.18 sits below the projected later-year averages, consistent with a longer-horizon upside scenario.
In the near term, the forecast shows limited upside in 2026 and 2027 but rising optimism from 2028 through 2050, with successive increases in the average price year by year in many years. The data imply a longer-term bullish potential, albeit with variability in the yearly lows and highs.
A major floor 38.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 57.4% above — a clean break opens room to run.
A major ceiling 76.5% above — clearing it would confirm fresh momentum.
Key TRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $16.66 | Sell | $16.74 | Sell |
| MA 10 | $17.13 | Sell | $17.23 | Sell |
| MA 20 | $18.82 | Sell | $18.11 | Sell |
| MA 50 | — | Neutral | — | Neutral |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.90 | Neutral |
| Stoch RSI (14) | 5.53 | Buy |
| CCI (20) | -93.85 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -17.40 | Sell |
| Bollinger %B (20,2) | 0.20 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | — | Neutral |
| Awesome (5,34) | -3.15 | Sell |
| Ultimate (7,14,28) | 38.63 | Neutral |
| Momentum (10) | -1.67 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 16.68 | Sell |
| ADX (14) | 10.32 | Neutral |
| ATR (14) | 1.00 | Info |
The 30-day technical picture is BEARISH overall, with RSI(14) at 50. The near-term range spans from $12.00 to $24.61, indicating a wide trading band over the last month.
Support is listed at $16.17 and resistance at $25.40, suggesting an uneven path near these levels. Annualized volatility is 100%, underscoring notable price swings within the period under review.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.14 | $16.14 | $21.07 | 0% | Neutral | |
| $10.29 | $15.84 | $26.35 | -2% | Neutral | |
| $11.76 | $19.98 | $36.03 | +24% | Bullish | |
| $11.38 | $21.12 | $40.48 | +31% | Bullish | |
| $11.37 | $22.93 | $46.20 | +42% | Bullish | |
| $9.55 | $20.90 | $43.97 | +29% | Bullish | |
| $8.44 | $18.75 | $40.96 | +16% | Neutral | |
| $9.57 | $21.27 | $48.07 | +32% | Bullish | |
| $10.27 | $22.82 | $52.48 | +41% | Bullish | |
| $12.67 | $28.15 | $64.74 | +74% | Bullish | |
| $14.75 | $32.77 | $75.37 | +103% | Bullish | |
| $19.64 | $43.65 | $100.39 | +170% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $16.14 | $16.14 | $19.49 | +0.00% |
| June 2026 | $13.94 | $17.06 | $21.86 | +5.71% |
| July 2026 | $13.14 | $16.50 | $21.91 | -3.29% |
| August 2026 | $12.06 | $15.45 | $21.07 | -6.38% |
| September 2026 | $12.06 | $15.71 | $21.90 | +1.69% |
| October 2026 | $11.90 | $15.75 | $22.39 | +0.29% |
| November 2026 | $10.87 | $14.59 | $21.09 | -7.38% |
| December 2026 | $10.55 | $14.35 | $21.07 | -1.66% |
Click any year to see its month-by-month TRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TRAX could reach as high as $21.07, with a base case around $16.14 and support toward $16.14 — roughly 0% from $16.14. Price action looks broadly range-bound.
Expect TRAX to range from $10.29 to $26.35 through 2027. The $15.84 average target implies a -2% move from current prices. That is -2% versus the projected 2026 average. A consolidation phase looks the most probable path here.
The TRAX price prediction for 2028 points to an average of $19.98 (low $11.76, high $36.03) — a potential gain of +24% on today's $16.14. Momentum favours further upside here.
In 2029, TRAX is projected to trade between $11.38 and $40.48, averaging $21.12 — a potential gain of +31% from today's $16.14. That is up +6% on the projected 2028 average. Buyers look set to stay in control over this stretch.
First Tracks Biotherapeutics, Inc.'s 2030 outlook centres on $22.93, within a $11.37 to $46.20 range. That is up +9% on the projected 2029 average. That marks a +42% change versus current levels. Momentum favours further upside here.
By 2031, TRAX could reach as high as $43.97, with a base case around $20.90 and support toward $9.55 — roughly +29% from $16.14. Buyers look set to stay in control over this stretch.
Expect TRAX to range from $8.44 to $40.96 through 2032. The $18.75 average target implies a +16% move from current prices. That is -10% versus the projected 2031 average. Price action looks broadly range-bound.
The TRAX price prediction for 2033 points to an average of $21.27 (low $9.57, high $48.07) — a potential gain of +32% on today's $16.14. Buyers look set to stay in control over this stretch.
In 2034, TRAX is projected to trade between $10.27 and $52.48, averaging $22.82 — a potential gain of +41% from today's $16.14. That is up +7% on the projected 2033 average. Momentum favours further upside here.
First Tracks Biotherapeutics, Inc.'s 2035 outlook centres on $28.15, within a $12.67 to $64.74 range. That is up +23% on the projected 2034 average. That marks a +74% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, TRAX could reach as high as $75.37, with a base case around $32.77 and support toward $14.75 — roughly +103% from $16.14. Momentum favours further upside here.
Expect TRAX to range from $19.64 to $100.39 through 2050. The $43.65 average target implies a +170% move from current prices. That is up +33% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRAX today (≈ 61.957869 TRAX) could be worth
$2,704.32
+$1,704.32 (+170%) by 2050 · US Dollar
Based on the average projected TRAX price of $43.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRAXwould be worth at today's price.
$1,000 invested in TRAX on Apr 6, 2026 (≈ 52.631579 TRAX) would be worth
$849.47
-$150.53 (-15.1%) today · 0.85× · US Dollar
Based on a TRAX entry price of $19 vs. today's $16.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.17 | $998.14 | -0.2% |
| 1 month ago | $18.1 | $891.71 | -10.8% |
| All time ago | $19 | $849.47 | -15.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRAX forecast.
Our base-case forecast reaches $32.00 around 2040.
Implied market cap at $32.00: $1.12B
The multi-year forecast shows a clear bullish trajectory beginning in 2028 and extending through 2050. In 2026 the average price is $17.18 with a min of $16.17 and a max of $23.08, and a neutral sentiment. By 2028 the average price rises to $24.47, with a max of $44.53 and a bullish stance, climbing further to $27.16 in 2030 for an average, with a max of $55.30 and a bullish outlook; the ROI for 2030 is 58.1%.
The year 2040 projects an average price of $45.20 and a max of $103.96, delivering a ROI of 163.1% with a bullish sentiment. By 2050 the forecast shows an average price of $58.68 and a max of $134.96, with a ROI of 241.6% and a bullish sentiment, indicating substantial upside potential.
Key mid-range years show continued bullish sentiment with growing averages: 2029 average $25.30 (ROI 47.3%), 2031 average $24.74 (ROI 44%), 2032 average $22.69 (ROI 32.1%), 2033 average $27.13 (ROI 57.9%). However, the path includes lower minima in some years (e.g., 2027 min $11.82; 2032 min $10.21), highlighting the spread of outcomes within the forecast.
Tap a question to reveal the answer.
2030 Avg $27.16; Min $13.22; Max $55.30; ROI 58.1%; Sentiment BULLISH.
Forecasts show bullish sentiment from 2028 onward with increasing averages (e.g., 2028 Avg $24.47, 2040 Avg $45.20, 2050 Avg $58.68) and positive ROIs (e.g., 58.1% in 2030, 163.1% in 2040, 241.6% in 2050). These are estimates, not guarantees.
Yes—2040 max is $103.96 and 2050 max is $134.96, indicating possible prices above $100 in later years.
Current price is $17.18 and market cap is $599.45M.
RSI(14) is 50 and sentiment is BEARISH. The 30-day range is $12.00 to $24.61, with support at $16.17 and resistance at $25.40, and annualized volatility of 100%.
First Tracks Biotherapeutics, Inc. Community Discussion
0Share your First Tracks Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.